PS
MGX icon

Principal Securities’s Metagenomi Therapeutics MGX Stock Holding History

Principal Securities’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-544
Closed -$1.29K – 3583
2025
Q3 		$1.29K Sell
544
-1,393
-72% -$2.83K ﹤0.01% 3336
2025
Q2 		$2.87K Buy
1,937
+500
+35% +$783 ﹤0.01% 3033
2025
Q1 		$5.19K Hold
1,437
– – ﹤0.01% 2760
2024
Q4 		$5.19K Buy
1,437
+750
+109% +$1.81K ﹤0.01% 2757
2024
Q3 		$1.49K Buy
687
+633
+1,172% +$2.2K ﹤0.01% 3035
2024
Q2 		$220 Hold
54
– – ﹤0.01% 3298
2024
Q1 		$570 Buy
+54
New +$621 ﹤0.01% 3127

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Principal Securities's MGX Position: Q4 2025 in Review

Principal Securities sold out of Metagenomi Therapeutics (MGX) in Q4 2025, closing a stake of 544 shares — an estimated $1.29K sold.

Principal Securities first reported a position in MGX in Q1 2024 and held it in 7 quarters. The position peaked at $5.19K in Q1 2025. 56 funds tracked by Wall St. Rank hold MGX as of Q4 2025.

  • Principal Securities reported no remaining Metagenomi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 544 Metagenomi Therapeutics shares in Q4 2025, an estimated $1.29K.
  • Principal Securities first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 7 quarters.
  • Principal Securities's Metagenomi Therapeutics position peaked at $5.19K in Q1 2025.
  • 56 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.